RESUMEN
BACKGROUND: Hemoglobinopathies constitute a major public health problem internationally, particularly in the developing world as it has the least resources for coping with the problem. Thalassemia is an inherited single-gene autosomal recessive disorder of the Red Blood Corpuscles (RBCs). Life becomes miserable due to blood transfusion every fortnight, recurrent infections, stunted growth, problems of iron overload, splenectomy, and decreased school performance. Nearly Rs. 1000 Crore is being spent in the treatment of thalassemia per annum. AIM: To evaluate the efficacy of Triphaladi Avaleha in Beejadushtijanya Pandu (thalassemia). MATERIALS AND METHODS: Total 32 patients of age group 1-15 years were registered and randomly divided into two groups. Group A (test drug treated group) and Group B (control group). In Group A, Triphaladi Avaleha was given with Godugdha, and in Group B, Deferiprone was administered. Assessment was done based on the subjective and objective parameters after 12 weeks of treatment, with a follow-up of 8 weeks. RESULTS: The trial drug proved better than the standard control in Paandutaa and Sandhishoola at a highly significant level and in Jwara, Akshikootashotha and Pindikodweshtana at a significant level. In Group A, five patients (38.46%) showed maximum improvement, five patients (38.46%) showed moderate improvement, two patients (15.38%) had mild improvement. CONCLUSION: Triphaladi Avaleha has various properties which help to relieve the signs and symptoms of the disease, as well as decrease the iron overload.
